David McDermott describes back-to-back publications in the Journal of Clinical Oncology that examine pembrolizumab in clear cell and non-clear cell renal cancer.
David McDermott describes back-to-back publications in the Journal of Clinical Oncology that examine pembrolizumab in clear cell and non-clear cell renal cancer.